Lung Cancer Diagnostics Market is expected to reach US$ 3.88 Bn. at a CAGR of 7.3% during the forecast period 2029. The Lung Cancer Diagnostics market report is a comprehensive analysis of the industry, market, and key players. The report has covered the market by demand and supply-side by segments. The global Lung Cancer Diagnostics report also provides trends by market segments, technology, and investment with a competitive landscape.To know about the Research Methodology:- Request Free Sample Report
Global Lung Cancer Diagnostics Market Overview:
The global lung cancer diagnostics market was valued at US$ 2.36 billion in 2022 and is expected to reach US$ 3.88 billion by 2029, at a CAGR of 7.3% during the forecasting period 2023-2029. The lung cancer that begins in the lungs most often occurs in the people who smoke more. Some of the symptoms of lung cancer are caught with blood, chest pain, and weight loss. There are a lot of treatments available in hospitals. Still, the cost of that treatment is too high, so normal people do not afford that cost, so the government is decided to make government hospitals where anyone can give treatment free of cost.Global Lung Cancer Diagnostics Market Dynamics:
Increasing the consumption of tobacco and rising cases of cervical cancer are increasing cancer cases, bolstering diagnostics prospects. Cervical cancer is the most common viral infection of the reproductive tract. Public and private associations, a joint effort to further develop a framework of analytic imaging communities, is driving a cellular breakdown in the lung of the demonstrative market. By the government and the health organization, they are trying to spread awareness about cancer globally. So it helps those people who show the same symptoms of cancer. The high cost of a diagnostic system is restraining the growth of the market. Moreover due to insufficient experience people, it causes a challenge for the market.Global Lung Cancer Diagnostics Market Segment Analysis:
The Global Lung Cancer Diagnostics Market is segmented into test, end-user, and indication. On the basis of test, global lung cancer diagnostics market is sub-segmented biomarkers tests, imaging tests, and biopsy. In the Biomarkers test, it includes some test and they are EGFR Mutation Test, KRAS Mutation Test, ALK Test, HER2 Test, and others. In imaging test, also includes Computed Tomography (CT) Scan, Positron Emission Tomography (PET) Scan, Chest X-RAY, and others. The Biopsy segment also includes tests like Needle Biopsy, Bronchoscopy Biopsy, Open Biopsy, and others. Among all the tests Imaging Tests is a more important test for diagnosis of lung cancer because it is very easy to understand the position and the size of the tumor. Imaging Tests, one of the segments analyzed in the report, is projected to grow at 8% CAGR to reach US$2.2 Billion by the end of the analysis period. Based on an end-user, the global lung cancer diagnostics market is sub-segmented into hospital associated labs, independent diagnostic laboratories, cancer research institutes, and others. According to the MMR reports, the hospital segment held the largest shares, xx%, in 2022. As it delivers well-organized, documented, retrieved, and logistical procedures. Hence, the hospital segment is expected to show fast growth due to rising the number of private hospitals, including many facilities in the hospital, quick treatment, and professional doctors. So many consumers are turning towards hospitals. Based on an indication, lung cancer is sub-segmented into non-small-cell lung cancer and small-cell lung cancer. Small cell cancers vary, depending on the expression of specific genes and cells. Generally, small cell cancer is more aggressive than non-small cell lung cancer. Non-small cell lung cancer (NSCLC) was identified as the largest segment, owing to the availability of novel diagnostic testing, detecting large tumor growths, and the most protuberant form in terms of occurrence, and accounting for nearly 81% of the disease. The reason behind that is the cancer virus directly attacks cells and stops flowing the blood, so due to less blood supply, people die. Nowadays, new technologies and treatments are going on, but the cost of that treatment is high.Recent Developments
In May 2022 Olympus corporation launched BF-UC190F treatment model which is helpful for the recovering the lung cancer. In Feb 2022 Intuitive surgical Inc. acquired Orpheus Medical which is in US. In Oct 2022 KLS Martin Group which is in Germany they are opened a new training center for lung cancer patients at its site is in Florida.Global Lung Cancer Diagnostics Market Regional Insights:
North America held the large share of the global lung cancer diagnostics market having xx% in 2022, and it can be attributed to the factors such as the increasing prevalence of cancer, rising recoveries in North America, and the introduction of favorable reimbursement policies, and there is some rule by the government in the US and Canada, due to all these North America lung cancer diagnostics market is growing. The data have provided by the National Cancer Institutes, which estimated the number of cases of cancer in the United Sated was 1.7 million in the year 2022, and it is expected to reach 20.3 million by 2029. APAC has the second-largest market is had the share xx % in the year 2022. The Asia Pacific is expected to show a fastest growth rate in the global lung cancer diagnostics market in the last few years due to government policies and a rise in awareness of the manufactures about lung cancer diagnostics and their benefits. The objective of the report is to present a comprehensive analysis of the global Lung Cancer Diagnostics market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding the global Lung Cancer Diagnostics market dynamics, structure by analyzing the market segments and project the global Lung Cancer Diagnostics market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the global Lung Cancer Diagnostics market make the report investor’s guide.Global Lung Cancer Diagnostics Market Scope: Inquire before buying
Global Lung Cancer Diagnostics Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 2.36 Bn. Forecast Period 2023 to 2029 CAGR: 7.3% Market Size in 2029: US $ 3.88 Bn. Segments Covered: by Test Biomarkers Tests Imaging Tests Biopsy by End User Hospital Associated Labs Independent Diagnostic Laboratories Cancer Research Institutes Others by Indication Non Small-cell Lung Cancer Small-cell Lung Cancer Global Lung Cancer Diagnostics Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Global Lung Cancer Diagnostics Market, Key Players are
1. Abbott Laboratories 2. Agilent Technologies Inc. 3. AMOY Diagnostics CO. LTD. 4.BD 5. Bio SB 6. Bio-Rad Laboratories 7. Biocartis NV 8. bioMerieux SA 9. Cancer Diagnostics Inc. 10. Danaher Corporation 11. DiaSorin S.P.A. 12. Exact Science 13. FUJIFILM Corporation 14. GE Healthcare 15. Hologic Inc. 16. Myriad Genetics Inc. 17. Quidel Corporation 18. Roche Diagnostics 19. Siemens Healthineers AG 20. Vela Diagnostics 21. Hoffmann-La Roche Ltd 22. Thermo Fisher Scientific 23. AstraZeneca plc 24. Illumina Inc. Frequently Asked Questions: 1. Which region has the largest share in Global Lung Cancer Diagnostics Market? Ans: North America region holds the highest share in 2022. 2. What is the growth rate of Global Lung Cancer Diagnostics Market? Ans: The Global Market is growing at a CAGR of 7.3% during forecasting period 2023-2029. 3. What is scope of the Global market report? Ans: Global Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global market? Ans: The important key players in the Global Market are – Abbott Laboratories, Agilent Technologies Inc., AMOY Diagnostics CO. LTD., BD, Bio SB, Bio-Rad Laboratories, Biocartis NV, bioMerieux SA, Cancer Diagnostics Inc., Danaher Corporation, DiaSorin S.P.A., Exact Science, FUJIFILM Corporation, GE Healthcare, Hologic Inc., Myriad Genetics Inc., Quidel Corporation, Roche Diagnostics, Siemens Healthineers AG, Vela Diagnostics, Hoffmann-La Roche Ltd, Thermo Fisher Scientific, AstraZeneca plc, and Illumina Inc. 5. What is the study period of this market? Ans: The Global Market is studied from 2022 to 2029.
1. Preface 1.1. Market Definition and Key Research Objectives 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Lung Cancer Diagnostics Market Size, by Market Value (US$ Bn) 3.1. Global Market Segmentation 3.2. Global Market Segmentation Share Analysis, 2021 3.2.1. Global 3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 3.3. Geographical Snapshot of the Lung Cancer Diagnostics Market 3.4. Geographical Snapshot of the Lung Cancer Diagnostics Market, By Manufacturer share 4. Global Lung Cancer Diagnostics Market Overview, 2022-2029 4.1. Market Dynamics 4.1.1. Drivers 4.1.1.1. Global 4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.2. Restraints 4.1.2.1. Global 4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.3. Opportunities 4.1.3.1. Global 4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.4. Challenges 4.1.4.1. Global 4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.5. Industry Trends and Emerging Technologies 4.1.6. Porters Five Forces Analysis 4.1.6.1. Threat of New Entrants 4.1.6.2. Bargaining Power of Buyers/Consumers 4.1.6.3. Bargaining Power of Suppliers 4.1.6.4. Threat of Substitute Products 4.1.6.5. Intensity of Competitive Rivalry 4.1.7. Value Chain Analysis 4.1.8. Technological Roadmap 4.1.9. Regulatory landscape 4.1.10. Impact of the Covid-19 Pandemic on the Global Lung Cancer Diagnostics Market 5. Supply Side and Demand Side Indicators 6. Global Lung Cancer Diagnostics Market Analysis and Forecast, 2022-2029 6.1. Global Lung Cancer Diagnostics Market Size & Y-o-Y Growth Analysis. 7. Global Lung Cancer Diagnostics Market Analysis and Forecasts, 2022-2029 7.1. Market Size (Value) Estimates & Forecast By Test, 2022-2029 7.1.1. Biomarkers Tests 7.1.1.1.1. EGFR Mutation Test 7.1.1.1.2. KRAS Mutation Test 7.1.1.1.3. ALK Test 7.1.1.1.4. HER2 Test 7.1.1.1.5. Others 7.1.2. Imaging Tests 7.1.2.1.1. Computed Tomography (CT) Scan 7.1.2.1.2. Positron Emission Tomography (PET) Scan 7.1.2.1.3. Chest X-RAY 7.1.2.1.4. Others 7.1.3. Biopsy 7.1.3.1.1. Needle Biopsy 7.1.3.1.2. Bronchoscopy Biopsy 7.1.3.1.3. Open Biopsy 7.1.3.1.4. Others 7.2. Market Size (Value) Estimates & Forecast By End User, 2022-2029 7.2.1. Hospital Associated Labs 7.2.2. Independent Diagnostic Laboratories 7.2.3. Cancer Research Institutes 7.2.4. Others 7.3. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 7.3.1. Non Small-cell Lung Cancer 7.3.2. Small-cell Lung Cancer 8. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By Region 8.1. Market Size (Value) Estimates & Forecast By Region, 2022-2029 8.1.1. North America 8.1.2. Europe 8.1.3. Asia-Pacific 8.1.4. Middle East & Africa 8.1.5. South America 9. North America Lung Cancer Diagnostics Market Analysis and Forecasts, 2022-2029 9.1. Market Size (Value) Estimates & Forecast By Test, 2022-2029 9.1.1. Biomarkers Tests 9.1.1.1.1. EGFR Mutation Test 9.1.1.1.2. KRAS Mutation Test 9.1.1.1.3. ALK Test 9.1.1.1.4. HER2 Test 9.1.1.1.5. Others 9.1.2. Imaging Tests 9.1.2.1.1. Computed Tomography (CT) Scan 9.1.2.1.2. Positron Emission Tomography (PET) Scan 9.1.2.1.3. Chest X-RAY 9.1.2.1.4. Others 9.1.3. Biopsy 9.1.3.1.1. Needle Biopsy 9.1.3.1.2. Bronchoscopy Biopsy 9.1.3.1.3. Open Biopsy 9.1.3.1.4. Others 9.2. Market Size (Value) Estimates & Forecast By End User, 2022-2029 9.2.1. Hospital Associated Labs 9.2.2. Independent Diagnostic Laboratories 9.2.3. Cancer Research Institutes 9.2.4. Others 9.3. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 9.3.1. Non Small-cell Lung Cancer 9.3.2. Small-cell Lung Cancer 10. North America Lung Cancer Diagnostics Market Analysis and Forecasts, By Country 10.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029 10.1.1. US 10.1.2. Canada 10.1.3. Mexico 11. U.S. Lung Cancer Diagnostics Market Analysis and Forecasts, 2022-2029 11.1. Market Size (Value) Estimates & Forecast By Test, 2022-2029 11.2. Market Size (Value) Estimates & Forecast By End User, 2022-2029 11.3. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 12. Canada Lung Cancer Diagnostics Market Analysis and Forecasts, 2022-2029 12.1. Market Size (Value) Estimates & Forecast By Test, 2022-2029 12.2. Market Size (Value) Estimates & Forecast By End User, 2022-2029 12.3. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 13. Mexico Lung Cancer Diagnostics Market Analysis and Forecasts, 2022-2029 13.1. Market Size (Value) Estimates & Forecast By Test, 2022-2029 13.2. Market Size (Value) Estimates & Forecast By End User, 2022-2029 13.3. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 14. Europe Lung Cancer Diagnostics Market Analysis and Forecasts, 2022-2029 14.1. Market Size (Value) Estimates & Forecast By Test, 2022-2029 14.2. Market Size (Value) Estimates & Forecast By End User, 2022-2029 14.3. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 15. Europe Lung Cancer Diagnostics Market Analysis and Forecasts, By Country 15.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029 15.1.1. U.K 15.1.2. France 15.1.3. Germany 15.1.4. Italy 15.1.5. Spain 15.1.6. Sweden 15.1.7. CIS Countries 15.1.8. Rest of Europe 16. U.K. Lung Cancer Diagnostics Market Analysis and Forecasts, 2022-2029 16.1. Market Size (Value) Estimates & Forecast By Test, 2022-2029 16.2. Market Size (Value) Estimates & Forecast By End User, 2022-2029 16.3. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 17. France Lung Cancer Diagnostics Market Analysis and Forecasts, 2022-2029 17.1. Market Size (Value) Estimates & Forecast By Test, 2022-2029 17.2. Market Size (Value) Estimates & Forecast By End User, 2022-2029 17.3. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 18. Germany Lung Cancer Diagnostics Market Analysis and Forecasts, 2022-2029 18.1. Market Size (Value) Estimates & Forecast By Test, 2022-2029 18.2. Market Size (Value) Estimates & Forecast By End User, 2022-2029 18.3. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 19. Italy Lung Cancer Diagnostics Market Analysis and Forecasts, 2022-2029 19.1. Market Size (Value) Estimates & Forecast By Test, 2022-2029 19.2. Market Size (Value) Estimates & Forecast By End User, 2022-2029 19.3. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 20. Spain Lung Cancer Diagnostics Market Analysis and Forecasts, 2022-2029 20.1. Market Size (Value) Estimates & Forecast By Test, 2022-2029 20.2. Market Size (Value) Estimates & Forecast By End User, 2022-2029 20.3. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 21. Sweden Lung Cancer Diagnostics Market Analysis and Forecasts, 2022-2029 21.1. Market Size (Value) Estimates & Forecast By Test, 2022-2029 21.2. Market Size (Value) Estimates & Forecast By End User, 2022-2029 21.3. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 22. CIS Countries Lung Cancer Diagnostics Market Analysis and Forecasts, 2022-2029 22.1. Market Size (Value) Estimates & Forecast By Test, 2022-2029 22.2. Market Size (Value) Estimates & Forecast By End User, 2022-2029 22.3. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 23. Rest of Europe Lung Cancer Diagnostics Market Analysis and Forecasts, 2022-2029 23.1. Market Size (Value) Estimates & Forecast By Test, 2022-2029 23.2. Market Size (Value) Estimates & Forecast By End User, 2022-2029 23.3. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 24. Asia Pacific Lung Cancer Diagnostics Market Analysis and Forecasts, 2022-2029 24.1. Market Size (Value) Estimates & Forecast By Test, 2022-2029 24.2. Market Size (Value) Estimates & Forecast By End User, 2022-2029 24.3. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 25. Asia Pacific Lung Cancer Diagnostics Market Analysis and Forecasts, by Country 25.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029 25.1.1. China 25.1.2. India 25.1.3. Japan 25.1.4. South Korea 25.1.5. Australia 25.1.6. ASEAN 25.1.7. Rest of Asia Pacific 26. China Lung Cancer Diagnostics Market Analysis and Forecasts, 2022-2029 26.1. Market Size (Value) Estimates & Forecast By Test, 2022-2029 26.2. Market Size (Value) Estimates & Forecast By End User, 2022-2029 26.3. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 27. India Lung Cancer Diagnostics Market Analysis and Forecasts, 2022-2029 27.1. Market Size (Value) Estimates & Forecast By Test, 2022-2029 27.2. Market Size (Value) Estimates & Forecast By End User, 2022-2029 27.3. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 28. Japan Lung Cancer Diagnostics Market Analysis and Forecasts, 2022-2029 28.1. Market Size (Value) Estimates & Forecast By Test, 2022-2029 28.2. Market Size (Value) Estimates & Forecast By End User, 2022-2029 28.3. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 29. South Korea Lung Cancer Diagnostics Market Analysis and Forecasts, 2022-2029 29.1. Market Size (Value) Estimates & Forecast By Test, 2022-2029 29.2. Market Size (Value) Estimates & Forecast By End User, 2022-2029 29.3. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 30. Australia Lung Cancer Diagnostics Market Analysis and Forecasts, 2022-2029 30.1. Market Size (Value) Estimates & Forecast By Test, 2022-2029 30.2. Market Size (Value) Estimates & Forecast By End User, 2022-2029 30.3. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 31. ASEAN Lung Cancer Diagnostics Market Analysis and Forecasts, 2022-2029 31.1. Market Size (Value) Estimates & Forecast By Test, 2022-2029 31.2. Market Size (Value) Estimates & Forecast By End User, 2022-2029 31.3. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 32. Rest of Asia Pacific Lung Cancer Diagnostics Market Analysis and Forecasts, 2022-2029 32.1. Market Size (Value) Estimates & Forecast By Test, 2022-2029 32.2. Market Size (Value) Estimates & Forecast By End User, 2022-2029 32.3. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 33. Middle East Africa Lung Cancer Diagnostics Market Analysis and Forecasts, 2022-2029 33.1. Market Size (Value) Estimates & Forecast By Test, 2022-2029 33.2. Market Size (Value) Estimates & Forecast By End User, 2022-2029 33.3. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 34. Middle East Africa Lung Cancer Diagnostics Market Analysis and Forecasts, by Country 34.1. Market Size (Value) Estimates & Forecast by Country, 2022-2029 34.1.1. South Africa 34.1.2. GCC Countries 34.1.3. Egypt 34.1.4. Nigeria 34.1.5. Rest of ME&A 35. South Africa Lung Cancer Diagnostics Market Analysis and Forecasts, 2022-2029 35.1. Market Size (Value) Estimates & Forecast By Test, 2022-2029 35.2. Market Size (Value) Estimates & Forecast By End User, 2022-2029 35.3. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 36. GCC Countries Lung Cancer Diagnostics Market Analysis and Forecasts, 2022-2029 36.1. Market Size (Value) Estimates & Forecast By Test, 2022-2029 36.2. Market Size (Value) Estimates & Forecast By End User, 2022-2029 36.3. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 37. Egypt Lung Cancer Diagnostics Market Analysis and Forecasts, 2022-2029 37.1. Market Size (Value) Estimates & Forecast By Test, 2022-2029 37.2. Market Size (Value) Estimates & Forecast By End User, 2022-2029 37.3. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 38. Nigeria Lung Cancer Diagnostics Market Analysis and Forecasts, 2022-2029 38.1. Market Size (Value) Estimates & Forecast By Test, 2022-2029 38.2. Market Size (Value) Estimates & Forecast By End User, 2022-2029 38.3. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 39. Rest of ME&A Lung Cancer Diagnostics Market Analysis and Forecasts, 2022-2029 39.1. Market Size (Value) Estimates & Forecast By Test, 2022-2029 39.2. Market Size (Value) Estimates & Forecast By End User, 2022-2029 39.3. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 40. South America Lung Cancer Diagnostics Market Analysis and Forecasts, 2022-2029 40.1. Market Size (Value) Estimates & Forecast By Test, 2022-2029 40.2. Market Size (Value) Estimates & Forecast By End User, 2022-2029 40.3. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 41. South America Lung Cancer Diagnostics Market Analysis and Forecasts, by Country 41.1. Market Size (Value) Estimates & Forecast by Country, 2022-2029 41.1.1. Brazil 41.1.2. Argentina 41.1.3. Rest of South America 42. Brazil Lung Cancer Diagnostics Market Analysis and Forecasts, 2022-2029 42.1. Market Size (Value) Estimates & Forecast By Test, 2022-2029 42.2. Market Size (Value) Estimates & Forecast By End User, 2022-2029 42.3. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 43. Argentina Lung Cancer Diagnostics Market Analysis and Forecasts, 2022-2029 43.1. Market Size (Value) Estimates & Forecast By Test, 2022-2029 43.2. Market Size (Value) Estimates & Forecast By End User, 2022-2029 43.3. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 44. Rest of South America Lung Cancer Diagnostics Market Analysis and Forecasts, 2022-2029 44.1. Market Size (Value) Estimates & Forecast By Test, 2022-2029 44.2. Market Size (Value) Estimates & Forecast By End User, 2022-2029 44.3. Market Size (Value) Estimates & Forecast By Indication, 2022-2029 45. Competitive Landscape 45.1. Geographic Footprint of Major Players in the Global Lung Cancer Diagnostics Market 45.2. Competition Matrix 45.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Applications and R&D Investment 45.2.2. New Product Launches and Product Enhancements 45.2.3. Market Consolidation 45.2.3.1. M&A by Regions, Investment and Verticals 45.2.3.2. M&A, Forward Integration and Backward Integration 45.2.3.3. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements 45.3. Company Profile : Key Players 45.3.1. Abbott Laboratories 45.3.1.1. Company Overview 45.3.1.2. Financial Overview 45.3.1.3. Geographic Footprint 45.3.1.4. Product Portfolio 45.3.1.5. Business Strategy 45.3.1.6. Recent Developments 45.3.2. Agilent Technologies Inc. 45.3.3. AMOY Diagnostics CO. LTD. 45.3.4. BD 45.3.5. Bio SB 45.3.6. Bio-Rad Laboratories 45.3.7. Biocartis NV 45.3.8. bioMerieux SA 45.3.9. Cancer Diagnostics Inc. 45.3.10. Danaher Corporation 45.3.11. DiaSorin S.P.A. 45.3.12. Exact Science 45.3.13. FUJIFILM Corporation 45.3.14. GE Healthcare 45.3.15. Hologic Inc. 45.3.16. Myriad Genetics Inc. 45.3.17. Quidel Corporation 45.3.18. Roche Diagnostics 45.3.19. Siemens Healthineers AG 45.3.20. Vela Diagnostics 45.3.21. Hoffmann-La Roche Ltd 45.3.22. Thermo Fisher Scientific 45.3.23. AstraZeneca plc 45.3.24. Illumina Inc. 46. Primary Key Insights